- Home
- Publications
- Publication Search
- Publication Details
Title
Improving Systemic Chemotherapy for Bladder Cancer
Authors
Keywords
Bladder cancer, Transitional cell carcinoma, Urothelial carcinoma, Chemotherapy, Biologic agents, Targeted agents, Neoadjuvant therapy, Adjuvant therapy, Trimodality therapy, Immunotherapy, Molecular biology, Prognostic factors, Personalized therapy
Journal
Current Oncology Reports
Volume 18, Issue 5, Pages -
Publisher
Springer Nature
Online
2016-03-18
DOI
10.1007/s11912-016-0512-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
- (2015) Matthew D. Galsky et al. CANCER
- Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
- (2015) Homayoun Zargar et al. EUROPEAN UROLOGY
- Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
- (2015) Cora N Sternberg et al. LANCET ONCOLOGY
- The Safety and Efficacy of Single-Agent Pemetrexed in Platinum-Resistant Advanced Urothelial Carcinoma: A Large Single-Institution Experience
- (2015) R. M. Bambury et al. ONCOLOGIST
- A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma
- (2014) Maha Hussain et al. CANCER
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity
- (2014) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
- (2014) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- Phase II study of everolimus in metastatic urothelial cancer
- (2013) Matthew I. Milowsky et al. BJU INTERNATIONAL
- Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
- (2013) Jeffrey J. Leow et al. EUROPEAN UROLOGY
- Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
- (2013) Yoo-Joung Ko et al. LANCET ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Results From the National Cancer Database
- (2013) Harras B. Zaid et al. UROLOGY
- Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
- (2012) E. Seront et al. ANNALS OF ONCOLOGY
- Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma
- (2012) Yu-Ning Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
- (2012) Andrea Necchi et al. LANCET ONCOLOGY
- Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
- (2012) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
- (2011) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
- (2011) F. Cognetti et al. ANNALS OF ONCOLOGY
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
- (2011) M. D. Galsky et al. ANNALS OF ONCOLOGY
- Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer
- (2011) Robert Rosenblatt et al. EUROPEAN UROLOGY
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
- (2011) Noah M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- (2011) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
- (2011) JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- Relative Efficacy of Perioperative Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Adriamycin, and Cisplatin in the Management of Locally Advanced Urothelial Carcinoma of the Bladder
- (2011) Olga Yeshchina et al. UROLOGY
- A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results
- (2010) Raj S. Pruthi et al. BJU INTERNATIONAL
- The COXEN Principle: Translating Signatures of In vitro Chemosensitivity into Tools for Clinical Outcome Prediction and Drug Discovery in Cancer
- (2010) S. C. Smith et al. CANCER RESEARCH
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
- (2010) Srikala S. Sridhar et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
- (2010) David J. Gallagher et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
- (2010) Guru Sonpavde et al. LANCET ONCOLOGY
- Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium
- (2009) Daniel P. Petrylak et al. BJU INTERNATIONAL
- Phase 2 trial of sorafenib in patients with advanced urothelial cancer
- (2009) Robert Dreicer et al. CANCER
- A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
- (2009) Christian Wülfing et al. CANCER
- Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma
- (2009) David J. Vaughn et al. CANCER
- Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
- (2009) Guru Sonpavde et al. CANCER
- Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study
- (2009) Florence Joly et al. Clinical Genitourinary Cancer
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Bladder cancer
- (2009) Donald S Kaufman et al. LANCET
- A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder
- (2008) Atreya Dash et al. CANCER
- Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial
- (2008) Kevin S. Oh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I-II RTOG Study (99-06) of Patients With Muscle-Invasive Bladder Cancer Undergoing Transurethral Surgery, Paclitaxel, Cisplatin, and Twice-daily Radiotherapy Followed by Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy
- (2008) Donald S. Kaufman et al. UROLOGY
- Fibroblast Growth Factor Receptor 3 Mutations in Bladder Tumors Correlate with Low Frequency of Chromosome Alterations
- (2008) Kerstin Junker et al. NEOPLASIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now